In Vivo Protein Homeostasis Network Manipulation in Rhabdomyosarcoma | Oncotarget

Описание: Oncotarget #published this #trending research paper on August 29, 2025, in Volume 16, entitled “In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma" by #researchers from the Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA; Department of Pediatrics, Georgetown University, Washington, DC; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA; Chan Zuckerberg Biohub, San Francisco, CA; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA; Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA. ‪@ucsf‬
#cancer #rhabdomyosarcoma #oncology #research #openaccess #openscience #peerreview #journal #publication #publishing #meded

DOI - https://doi.org/10.18632/oncotarget.2...

Correspondence to - Amit J. Sabnis - [email protected]

Abstract

The protein homeostasis (proteostasis) network includes quality control systems that coordinate protein synthesis, folding, localization, and degradation, and is deregulated in numerous diseases including cancer. Loss of proteostasis can activate lethal cellular stress responses, potentially opening a therapeutic window. Previous research demonstrated that MAL3-101, an inhibitor of heat shock protein 70-kD (HSP70) chaperones, selectively induces rhabdomyosarcoma (RMS) cell death via unfolded protein response (UPR) activation. RMS is the most common pediatric soft tissue sarcoma, and relapsed patients are rarely cured despite transient responses to DNA-damaging therapy. To examine whether MAL3-101 or more drug-like proteostasis inhibitors represent a new therapeutic strategy for RMS, we screened proteostasis components that might recapitulate the effects of MAL3-101 in vivo. We find that inhibition of VCP, which encodes the p97 ATPase that facilitates proteasome-dependent degradation, similarly activates the UPR and induces RMS apoptosis. In mouse models, a preclinical p97 inhibitor showed superior bioavailability and anti-tumor activity compared to MAL3-101. Patient-derived xenografts exhibited a spectrum of p97 inhibitor sensitivities, and RNA sequencing of resistant tumors revealed elevated autophagy, nominating a biomarker of proteostasis adaptability. Together, these findings confirm that proteostasis inhibition can slow RMS growth and suggest that targeting compensatory network components might yield synergistic outcomes.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/deta...

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, protein homeostasis, rhabdomyosarcoma, unfolded protein response, preclinical therapeutics, p97

About Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook -   / oncotarget  
X -   / oncotarget  
Instagram -   / oncotargetjrnl  
YouTube -    / @oncotargetjournal  
LinkedIn -   / oncotarget  
Pinterest -   / oncotarget  
Reddit -   / oncotarget  
Spotify - https://open.spotify.com/show/0gRwT6B...

Media Contact
[email protected]
18009220957